Health Condition 1: C00-D49- Neoplasms
Conditions
Interventions
Intervention1: Tablet Olanzapine 2.5 mg: Tablet Olanzapine 2.5 mg PO (per oral)at night(HS) once daily for 4 weeks
Control Intervention1: Tablet Folic acid 5mg: Tablet Folic acid 5 mg PO(per oral) at
Sponsors
Jefrilla Nancy J
Eligibility
Inclusion criteria
Inclusion criteria: Histologically/cytologically confirmed case of cancer Anorexia in a patient with cancer having VAS score
Exclusion criteria
Exclusion criteria: 1. Patients with known allergy to olanzapine 2. Patients with history of inability to tolerate olanzapine 3. Patients undergoing treatment either with chemotherapy, radiotherapy or surgery within 4 weeks of time before intiation of study 4. Patients on enteral feeding like Nasogastric,nasojejunal,PEG tubes 5. Patient with dysphagia or gastro intestinal obstruction 6. Patient with history of use of Megesterol Acetate/corticosteroids in previous 4 weeks 7. Patients already on statins and or oral/injectable hypoglycemic drugs 8. Patients with a known psychiatric disorder and taking anti psychotics 9. Patient is mentally incapacitated or has a severe emotional or psychiatric disorder, that in the opinion of the study investigator, precludes study entry 10.Patients not consenting for the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To assess the effect of olanzapine on the appetie and compare it with placeboTimepoint: 4 weeks | — |
Secondary
| Measure | Time frame |
|---|---|
| To compare the body weight and BMI of both the study arm To assess other symptoms using R-ESAS in both arms Timepoint: 4 weeks | — |
Countries
India
Contacts
Public ContactDr Kalpana Balakrishnan
Cancer Institute (WIA)
Outcome results
None listed